Biostage (BSTG) Stock Price, News & Analysis

Company Overview

Biostage, Inc. is a biotechnology company focused on regenerative medicine and the development of bioengineered organs. Its work has centered on using a patient’s own cells with biodegradable scaffolds to create replacement tissues intended to restore or replace damaged organs.

The company’s primary development program has involved an engineered esophageal implant for patients with severe esophageal disease or injury. Biostage has also described its Cellframe technology as a platform for producing living tissue constructs designed to support tissue regeneration while reducing the risk of immune rejection associated with donor organs.

Biostage was formerly known as Harvard Apparatus Regenerative Technology, Inc. The company’s activities have primarily involved research and clinical development in the United States. Information about its current commercial operations, product availability, and leadership is limited, and its technologies remain in the development stage rather than being broadly marketed medical products.

Key Stats

• Today's Range: $4.45 to $4.45
• 50-Day Range: $4.45 to $4.45
• 52-Week Range: $4.45 to $4.45
• Volume: N/A
• Average Volume: 1,847 shs
• Market Capitalization: $61.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Biostage Stock Analysis - MarketRank™

Biostage scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biostage has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biostage has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biostage is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biostage is -7.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BSTG.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biostage does not currently pay a dividend.

Dividend Growth

Biostage does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for BSTG on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biostage insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.30% of the stock of Biostage is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Biostage has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2020
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:BSTG
• CIK: 1563665
• Web: www.biostage.com
• Phone: (744) 233-7300
• Fax: 774-233-7302
• Employees: 7
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -174.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.26) per share
• Price / Book: -17.12

Miscellaneous

• Outstanding Shares: 13,882,000
• Free Float: 11,758,000
• Market Cap: $61.77 million
• Optionable: Not Optionable
• Beta: -1.02